Carlsmed (CARL) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
22 Apr, 2026Executive summary
Annual meeting scheduled for June 3, 2026, at 8:00 A.M. Pacific Time in San Diego, CA.
Shareholders are encouraged to review proxy materials and vote by June 2, 2026.
Voting can be done online, by mail, or in person at the meeting.
Voting matters and shareholder proposals
Election of two Class I directors, Niall Casey and Philip Young, for a three-year term expiring at the 2029 annual meeting.
Ratification of Ernst & Young LLP as independent registered public accounting firm for fiscal year ending December 31, 2026.
Proxy holders may vote on other business that arises at the meeting or any adjournment.
Board of directors and corporate governance
Board recommends voting in favor of both director nominees and the auditor ratification.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Carlsmed
- Personalized AI spine surgery platform accelerates growth with new reimbursement and strong clinical data.CARL
Bank of America SMID Cap Virtual Conference - Q2 revenue up 57% YoY to $18.9M; guidance raised on strong demand and CMS reimbursement changes.CARL
Q2 2026 - AI-powered personalized surgery platform drives rapid growth, high margins, and strong differentiation.CARL
Truist Securities MedTech Conference 2026 - Personalized spine surgery tech sees rapid adoption, strong outcomes, and margin expansion.CARL
Bank of America Global Healthcare Conference 2026 - Personalized AI-enabled spine surgery platform drives growth, clinical impact, and premium reimbursement.CARL
Corporate presentation - Q1 2026 revenue up 58% to $16.1M, gross margin 77.1%, and guidance raised to $72–77M.CARL
Q1 2026 - Proxy covers director elections, auditor ratification, governance, compensation, and ESG oversight.CARL
Proxy filing - AI-driven personalized spine surgery platform drives strong growth and clinical outcomes.CARL
25th Annual Needham Virtual Healthcare Conference - 2025 revenue surged 86% with robust margins and new launches; 2026 outlook remains strong.CARL
Q4 2025